Biogen To Discontinue The Development And Commercialization Of Aduhelm And Will Terminate The Envision Clinical Study And It Will Continue To Advance Leqembi (Lecanemab) And Will Accelerate Developing Potential New Treatment Modalities
Portfolio Pulse from Benzinga Newsdesk
Biogen has announced the discontinuation of Aduhelm's development and commercialization, including the termination of the ENVISION clinical study. The company will focus on advancing Leqembi (Lecanemab) and accelerating the development of new treatment modalities. The decision is not due to safety or efficacy concerns, and resources from the Aduhelm program will be redirected to Biogen's Alzheimer's disease franchise.
January 31, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's decision to stop Aduhelm's development and focus on Leqembi may impact investor sentiment and reallocate company resources, potentially affecting its stock price.
While the discontinuation of Aduhelm removes a product from Biogen's pipeline, the reallocation of resources to Leqembi and other treatments could be seen as a strategic move to strengthen its Alzheimer's disease franchise. The impact on the stock price is uncertain as it depends on investor perception of the potential of Leqembi and new treatments versus the loss of Aduhelm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100